Member Info for Krone

Really? It's still on the website http://www.sareum.com/news/events/

Good place for a major announcement....or will we Tim/John withdraw?

Let’s hope so. My situation isn’t entirely dissimilar. Hope to be able to retire within the next 12 months on the back of Sar.

Thoth2 are you that confident in Sareum that you would risk your life savings?

will either be confirming the date of the AGM, issue of options, milestone payment, confirmation of patent issue, or something BIG...

...one of Parker”s other interests is moving today!

Until last week the events tab on the Sareum website indicated that we would be represented at the ESMO conference which commenced on 19th. Today the events tab makes no reference to ESMO. How do the conspiracy theorists amongst us view this?

Given that we reportedly have 2 best/first in class Tyk2 molecules with multiple applications and a Chk1 molecule which is reportedly progressing at pace, what do people think would be the minimum acceptable offer that Tim/John and Parker would accept in terms of value and timescales?

Bristol-Myers embraces a possible checkpoint collaborator, snagging a batch of stock and lining up a potential deal by john carroll — on October 11, 2018 10:31 AM EDT PDF PDF Bristol-Myers Squibb $BMY is buddying up with a little biotech that just might have the key to unlocking a checkpoint strategy for one block of cancer patients. The big PD-1 player is investing $12 million at a premium price in Compugen, intrigued by early preclinical data that indicate there could be real potential for their checkpoint strategy. That’s not a huge sum, but it’s a clear indication of interest from Bristol-Myers Squibb, which has lined up first rights to negotiating a licensing pact with Compugen.

...if we are where we think we are...

So if/when a deal is done and assuming it's with a US based outfit, when would the RNS hit, 1430?

Zylo - Thanks for the clarification.

Seems like Sierra's focus is shifting from SRA737 to Momelotinib which it describes as 'the company's lead drug candidate'....

No mention in the Final Results of the previously referenced formulation issues. In the absence of resolution it is surely unlikely that a licence partner will step forward anytime soon.

Yes, surely the clue is in 'The Directors will continue to review the potential higher value of a later-stage licensing deal versus the requirement for any extra funding'

...or not?

Another tweet...this is becoming almost torrential! A Dual Inhibition, a Better Solution: Development of a JAK1/TYK2 inhibitor "dual inhibition of JAK1 and TYK2 can lead to a clinical benefit at a well-tolerated dosing regimen" pubs.acs.org/doi/10.1021/ac… $SAR.L Sareum #TYK2 #JAK1

Thanks Oldsilkroad/N4 - I was reading 'Closely related molecules, including SAR-20347' from the previous RNS as indicating that while closely related, the molecule is actually different.

So we are still waiting for formal selection of the SAR-20347 molecule?

Thanks Thoth2 that all sounds extremely positive.